Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Inclusion Criteria Main Selection Criteria for Healthy Volunteers: * Subject has provided written consent. * Subject is in general good health. * Females must be post-menopausal for at least 2 years or surgically sterile. * Females must not be pregnant or breast-feeding. If male, subject is surgically sterile or practicing specific forms of birth control. Main Selection Criteria for HCV Genotype 1-infected Volunteers: * Subject has provided written consent. * Subject has chronic HCV genotype 1 infection at screening. * Liver biopsy within 3 years with histology. * Females must be post-menopausal for at least 2 years or surgically sterile. * Females must not be pregnant or breast-feeding. If male, subject is surgically sterile or practicing specific forms of birth control. * Subject is in general good health, as perceived by the investigator, other than HCV infection. Main Selection Criteria for Volunteers in the Resistance Monitoring Portion of the Study: * Subject has provided written consent, has received at least one dose of ABT-267 or placebo in the study, and is considered suitable by the investigator to participate. Exclusion Criteria Main Exclusion Criteria for Healthy Volunteers: * Positive test for HAV IgM, HBsAg, HCV Ab or HIV Ab. * Clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder. * Use of tobacco or nicotine-containing products with the 6-month period prior to study drug administration. * Abnormal screening laboratory results. * Significant sensitivity to any drug. * Requirement for any over the counter and/or prescription medication, vitamins and/or herbal supplements on a regular basis. Main Exclusion Criteria for HCV Genotype 1-infected Volunteers: * Significant sensitivity to any drug. * Positive HBsAg, HAV-IgM, and HIV Ab. Use of CYP enzyme inducers or inhibitors within 1 month of dosing. * Clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid disease (except hypothyroidism on stable thyroid replacement therapy), or any uncontrolled medical illness or psychiatric disorder. * Use of any medications (prescription and over-the counter) within 2 weeks prior to study drug dosing without prior approval by the Abbott Medical Monitor. * Use of any vitamins or herbal supplements within 2 weeks prior to study drug dosing. * Prior treatment with any investigational or commercially available anti-HCV agents. * Abnormal screening laboratory results.